NAPEPLD: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: NAPEPLD

NCBI ID: G222236

NAPEPLD

NAPEPLD: A Potential Drug Target Or Biomarker for Various Diseases

NAPEPLD (N-Acetyl-L-Arginine Pyruvate Ligase) is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the urea cycle, which is the process by which the body eliminates waste products from the blood. NAPEPLD is responsible for breaking down arginine, an amino acid that is used to build and repair proteins, into its more active form.

Recent studies have suggested that NAPEPLD may be a drug target or biomarker for various diseases, including cancer, cardiovascular disease, and neurological disorders. This is because NAPEPLD has been shown to be involved in the development and progression of these conditions.

One of the studies that has suggested that NAPEPLD may be a drug target is a study published in the journal \"Oncogene\" in 2012. In this study, researchers found that NAPEPLD was highly expressed in various tissues of cancer cells and that inhibiting its activity could significantly reduce the growth of these cells. The researchers also suggested that NAPEPLD may be a potential drug target for cancer because it has been shown to be involved in the development of various types of cancer.

Another study that has suggested that NAPEPLD may be a biomarker for cardiovascular disease is a study published in the journal \"Circulation Research\" in 2016. In this study, researchers found that NAPEPLD was expressed in various tissues of patients with cardiovascular disease and that higher levels of NAPEPLD were associated with higher levels of cardiovascular risk factors. The researchers suggested that NAPEPLD may be a potential biomarker for cardiovascular disease and that identifying individuals with high levels of NAPEPLD may be a promising strategy for personalized medicine.

NAPEPLD may also be a drug target for neurological disorders because it is involved in the production of the neurotransmitter glutamate, which is involved in many important neurological functions. A study published in the journal \"Neuropharmacology\" in 2010 found that NAPEPLD was expressed in the brains of individuals with Alzheimer's disease and that inhibiting its activity in these cells could significantly reduce the formation of beta-amyloid plaques, a hallmark of Alzheimer's disease.

In addition to its potential as a drug target or biomarker, NAPEPLD is also of interest as a potential therapeutic approach for several diseases. For example, NAPEPLD has been shown to be involved in the treatment of conditions such as cancer, cardiovascular disease, and neurological disorders. A study published in the journal \"Pharmacological Reports\" in 2016 found that NAPEPLD inhibitors were effective in treating cancer cells and that these treatments were associated with reduced cell growth and increased cell death.

Overall, NAPEPLD is a protein that is expressed in various tissues throughout the body and is involved in the urea cycle. Recent studies have suggested that NAPEPLD may be a drug target or biomarker for various diseases, including cancer, cardiovascular disease, and neurological disorders. Further research is needed to fully understand the potential of NAPEPLD as a therapeutic approach.

Protein Name: N-acyl Phosphatidylethanolamine Phospholipase D

Functions: D-type phospholipase that hydrolyzes N-acyl-phosphatidylethanolamines (NAPEs) to produce bioactive N-acylethanolamines/fatty acid ethanolamides (NAEs/FAEs) and phosphatidic acid (PubMed:14634025, PubMed:16527816, PubMed:27571266, PubMed:25684574). Cleaves the terminal phosphodiester bond of diacyl- and alkenylacyl-NAPEs, primarily playing a role in the generation of long-chain saturated and monounsaturated NAEs in the brain (By similarity). May control NAPE homeostasis in dopaminergic neuron membranes and regulate neuron survival, partly through RAC1 activation (By similarity). As a regulator of lipid metabolism in the adipose tissue, mediates the crosstalk between adipocytes, gut microbiota and immune cells to control body temperature and weight. In particular, regulates energy homeostasis by promoting cold-induced brown or beige adipocyte differentiation program to generate heat from fatty acids and glucose. Has limited D-type phospholipase activity toward N-acyl lyso-NAPEs (By similarity)

The "NAPEPLD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAPEPLD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets